Zobrazeno 1 - 10
of 131
pro vyhledávání: '"Charbel, Moussa"'
Publikováno v:
Frontiers in Dementia, Vol 3 (2024)
Tyrosine kinases (TKs) are catalytic enzymes activated by auto-phosphorylation that function by phosphorylating tyrosine residues on downstream substrates. Tyrosine kinase inhibitors (TKIs) have been heavily exploited as cancer therapeutics, primaril
Externí odkaz:
https://doaj.org/article/601d1668ad0c41dcb9694638345e5985
Autor:
Max Stevenson, Rency Varghese, Michaeline L. Hebron, Xiaoguang Liu, Nick Ratliff, Amelia Smith, R. Scott Turner, Charbel Moussa
Publikováno v:
Journal of Neuroinflammation, Vol 20, Iss 1, Pp 1-12 (2023)
Abstract Discoidin Domain Receptor (DDR)-1 is activated by collagen. Nilotinib is a tyrosine kinase inhibitor that is FDA-approved for leukemia and potently inhibits DDR-1. Individuals diagnosed with mild–moderate Alzheimer’s disease (AD) treated
Externí odkaz:
https://doaj.org/article/e25ad3d27a9d4b9aa56025dd33e019df
Publikováno v:
Journal of Clinical and Translational Science, Vol 8, Pp 100-100 (2024)
OBJECTIVES/GOALS: Alzheimer’s Disease (AD) displays numerous pathological features, including amyloid-beta deposition, extensive neuroinflammation, and vascular fibrosis. However, putative therapeutic options for alleviating these features remain l
Externí odkaz:
https://doaj.org/article/1c9ca95ae458443895843aad38e369ad
Autor:
Fernando L. Pagan, Yasar Torres‐Yaghi, Michaeline L. Hebron, Barbara Wilmarth, R. Scott Turner, Sara Matar, Dalila Ferrante, Jaeil Ahn, Charbel Moussa
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 8, Iss 1, Pp n/a-n/a (2022)
Abstract Introduction Bosutinib, a dual Abelson/Src inhibitor, was investigated in individuals with dementia with Lewy bodies (DLB). Methods A single site, randomized, double‐blind, placebo‐controlled study of the effects of oral bosutinib, 100 m
Externí odkaz:
https://doaj.org/article/003e9803bd3344659874b1f34a070969
Autor:
Gregory D. Scott, Moriah R. Arnold, Thomas G. Beach, Christopher H. Gibbons, Anumantha G. Kanthasamy, Russell M. Lebovitz, Afina W. Lemstra, Leslie M. Shaw, Charlotte E. Teunissen, Henrik Zetterberg, Angela S. Taylor, Todd C. Graham, Bradley F. Boeve, Stephen N. Gomperts, Neill R. Graff-Radford, Charbel Moussa, Kathleen L. Poston, Liana S. Rosenthal, Marwan N. Sabbagh, Ryan R. Walsh, Miriam T. Weber, Melissa J. Armstrong, Jee A. Bang, Andrea C. Bozoki, Kimiko Domoto-Reilly, John E. Duda, Jori E. Fleisher, Douglas R. Galasko, James E. Galvin, Jennifer G. Goldman, Samantha K. Holden, Lawrence S. Honig, Daniel E. Huddleston, James B. Leverenz, Irene Litvan, Carol A. Manning, Karen S. Marder, Alexander Y. Pantelyat, Victoria S. Pelak, Douglas W. Scharre, Sharon J. Sha, Holly A. Shill, Zoltan Mari, Joseph F. Quinn, David J. Irwin
Publikováno v:
Frontiers in Neurology, Vol 12 (2022)
The Lewy Body Dementia Association (LBDA) held a virtual event, the LBDA Biofluid/Tissue Biomarker Symposium, on January 25, 2021, to present advances in biomarkers for Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLBs) and Par
Externí odkaz:
https://doaj.org/article/e84d47ecb7c4440da3c49a05adb2450e
Autor:
Karen E. Anderson, Max Stevenson, Rency Varghese, Michaeline L. Hebron, Erin Koppel, Mara McCartin, Robin Kuprewicz, Sara Matar, Dalila Ferrante, Charbel Moussa
Publikováno v:
Metabolites, Vol 12, Iss 12, p 1225 (2022)
Nilotinib is a tyrosine kinase inhibitor that is safe and tolerated in neurodegeneration, it achieves CSF concentration that is adequate to inhibit discoidin domain receptor (DDR)-1. Nilotinib significantly affects dopamine metabolites, including Hom
Externí odkaz:
https://doaj.org/article/cdae29a63dc94b07820a577e6b24285d
Autor:
Bethany Peterson, Melissa Armstrong, Douglas Galasko, James E. Galvin, Jennifer Goldman, David Irwin, Henry Paulson, Daniel Kaufer, James Leverenz, Angela Lunde, Ian G. McKeith, Andrew Siderowf, Angela Taylor, Katherine Amodeo, Matt Barrett, Kimiko Domoto-Reilly, John Duda, Stephen Gomperts, Neill Graff-Radford, Samantha Holden, Lawrence Honig, Daniel Huddleston, Carol Lippa, Irene Litvan, Carol Manning, Karen Marder, Charbel Moussa, Chiadi Onyike, Fernando Pagan, Alexander Pantelyat, Victoria Pelak, Kathleen Poston, Joseph Quinn, Irene Richard, Liana S. Rosenthal, Marwan Sabbagh, Douglas Scharre, Sharon Sha, Holly Shill, Yasar Torres-Yaghi, Tina Christie, Todd Graham, Ian Richards, Mike Koehler, Brad Boeve
Publikováno v:
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-4 (2019)
Abstract The first Lewy Body Dementia Association (LBDA) Research Centers of Excellence (RCOE) Investigator’s meeting was held on December 14, 2017, in New Orleans. The program was established to increase patient access to clinical experts on Lewy
Externí odkaz:
https://doaj.org/article/78d82e5caeeb47d5b89d124143fa80b8
Autor:
Katherine Michel, Christine Colie, Robert D. Burk, L. Stewart Massad, Cuiwei Wang, Michaeline Hebron, Charbel Moussa, Gypsyamber D’Souza, Lisa Rahangdale, Lisa Flowers, Joel Milam, Joel M. Palefsky, Howard Minkoff, Howard D. Strickler, Seble G. Kassaye
Publikováno v:
Journal of Clinical and Translational Science, Vol 5, Pp 23-24 (2021)
ABSTRACT IMPACT: The potential to use vaginal pH as a low cost, non-invasive diagnostic test at the point of CIN2 diagnosis to predict worsening of cervical disease. OBJECTIVES/GOALS: We previously reported that persistence/progression of cervical in
Externí odkaz:
https://doaj.org/article/0d37e9d4f3614efeb394caacfc995ce1
Autor:
Xiaoguang Liu, Kaluvu Balaraman, Ciarán C. Lynch, Michaeline Hebron, Christian Wolf, Charbel Moussa
Publikováno v:
Metabolites, Vol 11, Iss 9, p 622 (2021)
Ubiquitin Specific Protease-13 (USP13) promotes protein de-ubiquitination and is poorly understood in neurodegeneration. USP13 is upregulated in Alzheimer’s disease (AD) and Parkinson’s disease (PD), and USP13 knockdown via shRNA reduces neurotox
Externí odkaz:
https://doaj.org/article/0d639b46acf64c7a9e4fe1bd9598fe02
Autor:
Max Stevenson, Rency Varghese, Michaeline Hebron, Xiaoguang Liu, Nick Ratliff, Amelia Smith, R. Scott Turner, Charbel Moussa
Discoidin Domain Receptor (DDR)-1 is activated by collagen. Nilotinib is a tyrosine kinase inhibitor that is FDA-approved for leukemia and potently inhibits DDR-1. Individuals diagnosed with mild-moderate Alzheimer’s disease (AD) treated with nilot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::627320c1abdde0d1ba5ff9195e4a7a74
https://doi.org/10.21203/rs.3.rs-2705486/v1
https://doi.org/10.21203/rs.3.rs-2705486/v1
